Michael Alexander Smith Sells 1,053 Shares of Insmed (NASDAQ:INSM) Stock

08 Jan 2026, 19:21 by Doug Wharley · The Cerbat Gem

Insmed, Inc. (NASDAQ:INSM – Get Free Report) insider Michael Alexander Smith sold 1,053 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $174.17, for a total value of $183,401.01. Following the completion of the transaction, the insider directly owned 57,037 shares in the company, valued at $9,934,134.29. This represents a 1.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Michael Alexander Smith also recently made the following trade(s):

On Wednesday, January 7th, Michael Alexander Smith sold 709 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total value of $124,124.63.
On Tuesday, January 6th, Michael Alexander Smith sold 1,396 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total value of $241,968.68.
On Monday, November 3rd, Michael Alexander Smith sold 27,130 shares of Insmed stock. The shares were sold at an average price of $183.78, for a total value of $4,985,951.40.

Insmed Trading Down 3.3%

INSM traded down $5.73 during trading on Thursday, reaching $170.27. The company had a trading volume of 2,588,589 shares, compared to its average volume of 2,142,398. The firm’s 50-day simple moving average is $190.79 and its 200 day simple moving average is $151.24. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. The company has a market cap of $36.31 billion, a price-to-earnings ratio of -27.51 and a beta of 1.08. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $212.75.

Insmed (NASDAQ:INSM – Get Free Report) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The firm had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. During the same quarter in the previous year, the business earned ($1.27) earnings per share. The business’s quarterly revenue was up 52.4% compared to the same quarter last year. Equities research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Royal Bank of Canada raised its holdings in shares of Insmed by 33.2% during the 1st quarter. Royal Bank of Canada now owns 245,262 shares of the biopharmaceutical company’s stock valued at $18,710,000 after purchasing an additional 61,190 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Insmed by 4.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 109,489 shares of the biopharmaceutical company’s stock worth $8,364,000 after purchasing an additional 4,176 shares in the last quarter. Caxton Associates LLP acquired a new position in Insmed during the first quarter worth $441,000. Woodline Partners LP raised its holdings in Insmed by 53.3% during the first quarter. Woodline Partners LP now owns 248,770 shares of the biopharmaceutical company’s stock valued at $18,979,000 after buying an additional 86,540 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Insmed by 10.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 539,484 shares of the biopharmaceutical company’s stock worth $41,157,000 after buying an additional 52,637 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Wells Fargo & Company set a $195.00 target price on Insmed in a research report on Thursday, December 18th. Royal Bank Of Canada reduced their price objective on Insmed from $215.00 to $195.00 and set an “outperform” rating for the company in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research report on Wednesday, October 8th. Wolfe Research set a $167.00 target price on Insmed and gave the company an “outperform” rating in a report on Thursday, December 18th. Finally, Mizuho set a $212.00 price target on shares of Insmed in a research report on Thursday, December 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $205.64.

Read Our Latest Analysis on Insmed

Insmed News Roundup

Here are the key news stories impacting Insmed this week:

Positive Sentiment: High-profile media attention — Jim Cramer singled out Insmed as “worth keeping an eye on,” which can attract retail interest and trading volume. Read More.
Neutral Sentiment: Public SEC disclosures: the insider sales were reported in Form 4 filings (transparent regulatory reporting), and insiders still retain large positions — meaning these may be planned sales rather than full exits. See aggregated reporting of recent insider transactions. Read More.
Negative Sentiment: Large, concentrated insider selling — multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and other insiders) sold thousands of shares across Jan. 6–8. Such clustered sales by top management often spook investors and can pressure the stock. One recent block sale by insider Orlov (87,290 shares, ~$15.3M) is particularly large and notable. Read More.
Negative Sentiment: Investor litigation risk — Pomerantz LLP announced an investigation into claims on behalf of Insmed investors, which raises legal/settlement risk and typically weighs on sentiment until resolved. Read More.

About Insmed

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.